Table 1 Patient characteristics, disease measures, and serum levels of Pro-C2 and C-Col10
From: Chondrocyte activity is increased in psoriatic arthritis and axial spondyloarthritis
axSpA (n = 110) | PsA (n = 101) | Control | |
|---|---|---|---|
Male sex, % | 72 % | 59 % | |
Age, years | 36.6 (35.3–38.0) | 37.0 (35.6–38.5) | |
BMI, kg/m2 | 25.5 (24.8–26.3) | 27.4 (26.2–28.5) | |
Smoker, % | 36 % | 35 % | |
HLA-B27 positive, % | 87 % | 20 % | |
Disease duration, years | 6.4 (5.4–7.5) | 6.7 (5.6–7.8) | |
VAS | |||
Patient global | 34 (29–39) | 39 (34–45) | |
Patient pain | 32 (27–37) | 32 (27–37) | |
Patient fatigue | 40 (34–45) | 43 (37–49) | |
Physician global | 4 [1–16] | 3 [1–14] | |
BASDAI | 31 (26–35) | 36 (31–41) | |
BASFI | 23 (19–27) | 27 (22–32) | |
BASMI | 10 [0–20] | 10 [0–10] | |
ASDAS (CRP) | 2.0 (1.8–2.3) | 2.1 (1.9–2.4) | |
Swollen joints, % | 9 % | 38 % | |
hs-CRP, mg/dl | 3 [1–7] | 3 [1–9] | |
Pro-C2, ng/ml | 1.11 [0.67-1.64] | 1.03 [0.53-1.47] | 0.30 [0.16-0.41] |
Col-X, ng/ml | 0.45 [0.28-0.67] | 0.42 [0.31-0.72] | 0.33 [0.31-0.45] |